Hepatitis B virus reactivation, including life threatening hepatitis B, was observed in the
clinical program.
Avacopan does not eliminate glucocorticoid use.
- TRADE NAME: Tavneos (ChemoCentryx)
- INDICATIONS:
Adjunct for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy including glucocorticoids.
- CLASS: Complement receptor antagonist
- HALF-LIFE: 97.6 hours
- FDA APPROVAL DATE: 10/07/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A4 inducers, CYP3A4 inhibitors, Itraconazole, Rifampin - PREGNANCY: No adequate and well-controlled studies with avacopan in pregnant women to inform a drug-associated risk.
Please login to view the rest of this drug profile.
Page last updated 01/23/2025
